Figure 1From: Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer Immunohistochemistry for pSrc and pFAK in hepatic metastases from colorectal cancer. The left panels demonstrate pSrc (Y416) staining in one patient before and after treatment with oxaliplatin chemotherapy (top and bottom, respectively). In the right panels, pFAK (Y861) staining demonstrates a similar pattern.Back to article page